Buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)

Name: Buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) - Planex Supplies
SKU: Fragment 176
Price: 87.00 USD
Availability: InStock

$87.00

Fragment 176-191 & CJC-1295 & Ipamorelin Triple Composite

This analysis provides a comprehensive assessment of the biochemical specifications, structural data, and preclinical research vectors for the triple-peptide composite containing Fragment 176-191, CJC-1295 (Modified GRF 1-29), and Ipamorelin. These molecules are evaluated collectively in laboratory models to study concurrent metabolic alterations and multi-channel neuroendocrine axis dynamics.

SKU: Fragment 176 Category: Peptide Blends Tags: Bone Density, Buy Peptides Online, Cartilage Repair, CJC-1295, Fragment 176-191, Ipamorelin, Lab Supplies, Lipolysis, Neuroendocrine, Peptide Blend, Planex Supplies, Research Peptides, Secretagogue, USA Tested

Description
Reviews (0)

Multi-Pathway Metabolic & Neuroendocrine Axis Signaling

The combination of Fragment 176-191, CJC-1295, and Ipamorelin establishes an advanced experimental matrix designed to investigate the growth hormone (GH) axis through distinct, non-competing mechanisms. While Fragment 176-191 targets peripheral adipocyte metabolic pathways, CJC-1295 and Ipamorelin function as separate neuroendocrine secretagogues targeting the Growth Hormone-Releasing Hormone Receptor (GHRHR) and the Ghrelin Receptor (GHS-R1a), respectively. This triple-action profile allows for the observation of immediate versus sustained somatotroph cell kinetics and localized structural tissue repair without direct receptor competition.

Comprehensive Technical Specifications:

Fragment 176-191 (hGH C-Terminal Fragment)

- Molecular Formula: $\text{C}_{78}\text{H}_{125}\text{N}_{23}\text{O}_{23}\text{S}_{2}$
- Molecular Weight: 1817.1 g/mol
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

CJC-1295 (Modified GRF 1-29) (Note: Synthesized without a Drug Affinity Complex [DAC] component)

- Molecular Formula: $\text{C}_{152}\text{H}_{252}\text{N}_{44}\text{O}_{42}$
- Molecular Weight: 3367.954 g/mol
- Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mal)-NH2

Ipamorelin (Highly Selective Pentapeptide GHS)

- Molecular Formula: $\text{C}_{38}\text{H}_{49}\text{N}_{9}\text{O}_{5}$
- Molecular Weight: 711.86 g/mol
- Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2

Key Areas of Preclinical Observation and Cellular Pathways:

- Isolated Lipolysis and Fat Mobilization: Fragment 176-191 isolates the C-terminal region of the human growth hormone molecule, which is hypothesized to target beta-3 adrenergic receptors ($ADRB3$) to amplify fat breakdown (lipolysis) and decrease fat storage (lipogenesis). Preclinical data indicates that it isolates these metabolic traits without triggering full-molecule growth factors like long-bone overgrowth, fluid retention (edema), or reduced insulin sensitivity, rendering it a clean framework for studying fat cell metabolism.
- Somatotroph Proliferation and Glycemic Balance: CJC-1295 functions as a stabilized GHRH analog engineered to resist rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). In animal models characterized by a GHRH gene deletion ($GHRHKO$), regular exposure to CJC-1295 has been observed to preserve standard weight, length, and lean mass composition without increasing adiposity. Immunohistochemistry data confirms that CJC-1295 upregulates total pituitary RNA and GH mRNA, indicating localized somatotroph cell proliferation and sustained growth hormone synthesis.
- Biphasic Neuroendocrine Secretion Kinetics: Investigators utilize this triple composite to analyze a balanced, biphasic pharmacokinetic model. Ipamorelin exhibits a brief 2-hour half-life and delivers a rapid, immediate pulse of growth hormone by stimulating insulin release through intracellular calcium channels and adrenergic receptor pathways. Conversely, CJC-1295 exerts a long-term influence to sustain standard physiological secretion patterns over an extended duration. Combining the two allows researchers to track immediate response spikes alongside sustained baseline availability.
- Skeletal Mineralization and Chondrocyte Activation: Beyond systemic metabolism, both Ipamorelin and Fragment 176-191 are evaluated for structural tissue repair. In joint modeling, the growth hormone fragment has demonstrated an ability to facilitate cartilage matrix regeneration. Concurrently, real-time dual X-ray absorptiometry (DXA) and mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans indicate that Ipamorelin acts directly on osteoblasts to expand total bone cross-sectional area, tibial dimensions, and vertebral bone mineral content (BMC), offering a robust platform for studying cell-aging mitigation.

Safety, Quality Standards, and Regulatory Status

These compounds are classified strictly as research chemicals and are not approved for human or veterinary consumption, diagnosis, or clinical therapy by regulatory bodies such as the FDA. For high-integrity laboratory data, these peptides must be synthesized to maximum purity standards, typically verified via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry profiling to confirm correct molecular mass fractions and the complete absence of residual cross-contaminants. Make sure to double-check the physical label to confirm this information.